Schmerzpraxis Wiesbaden

Publikationen PD Dr. Kernbuecherregal

 

  1. Kern U., Martin C., Scheicher S., Müller H. (2003)
    Treatment of phantom pain with botulinum-toxin A.
    A pilot study
    Schmerz 17, 117-124
     
  2. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Long-term treatment of phantom- and stump pain with Botulinum toxin type A over 12 months.
    A first clinical observation
    Nervenarzt 75, 336-340
     
  3. Kern U., Martin C., Scheicher S., Müller H. (2006)
    Referred pain from amputation stump trigger points into the phantom limb.
    Schmerz 20, 300, 302-306
     
  4. Kern U., Busch V., Rockland M., Kohl M., Birklein F. (2009)
    Prevalence and risk factors of phantom limb pain and phantom limb sensations in Germany.
    A nationwide field survey
    Schmerz 23, 479-488
     
  5. Kern U., Kohl M., Kiefer R.-T. (2010)
    Lidocaine patch for therapy of neuropathic and non-neuropathic pain: A clinical case series of 87 patients.
    Nervenarzt 81, 1490-1497
     
  6. Kern U., Altkemper B., Kohl M. (2006)
    Management of phantom pain with a textile, electromagnetically-acting stump liner: a randomized, double-blind, crossover study
    J Pain Symptom Manage 32, 352-360
     
  7. Kern U., Kohl M., Seifert U., Schlereth T. (2011)
    Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study.
    Am J Phys Med Rehabil 90, 321-329
     
  8. Kern U., Martin C., Scheicher S., Müller H. (2003)
    Botulinum toxin type A influences stump pain after limb amputations.
    J Pain Symptom Manage 26, 1069-1070
     
  9. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Effects of botulinum toxin type B on stump pain and involuntary movements of the stump.
    Am J Phys Med Rehabil 83, 396-399
     
  10. Kern U. (2004)
    Influence of botulinum toxin on postamputation pain and phantom limbs.
    J Neurol Feb 251 Suppl 1, I/42
     
  11. Kern U., Martin C., Scheicher S., Müller H. (2004)
    Does botulinum toxin A make prosthesis use easier for amputees?
    J Rehabil Med 36, 238-239
     
  12. Koch H., Kern U., Busch V. (2009)
    Therapeutische Wirkung von Ausdauersport bei Migräne: Explorative Metaanalyse sportmedizinischer Studien.
    MMW-Forschritte der Medizin Originalien Nr.II, 59-62
     
  13. Reilich P., Fheodoroff K., Kern U., Mense S., Seddigh S., Wissel J., et al. (2004)
    Consensus statement: botulinum toxin in myofascial pain.
    J Neurol 251 Suppl 1, I36-38
     
  14. England J., Wagner T., Kern U., Roth-Daniek A., Sell A. (2011)
    The capsaicin 8% patch for peripheral neuropathic pain: practical guidance, hints and tips on the application process.
    Br J Nurs. 2011 Aug 11-Sep 8;20(15):926-31
     
  15. Kern U., Kohl M., Seifert U., Schlereth T. (2012)
    Botulinumtoxin Typ B lindert Stumpfschmerzen und Stumpfschwitzen - Chance zur indirekten Phantomschmerz-Reduktion durch bessere Prothesen-Nutzung?
    Schmerz. 2012 Apr;26(2):176-84
     
  16. Kern U., Busch V., Mueller R., Kohl M., Birklein F. (2012)
    Phantom limb pain in daily pratice - still a lot of work to do!
    Pain Med. 2012 Sep 26. doi:10.1111/j.1526-4637.2012.01494.x
     
  17. Mick G., Baron R., Kern U., Hans G., Finnerup N. B., Dworkin R. H. (2011)
    Localized neuropathic pain: clinical characteristics and a proposed definition.
    Pain Manage. (2012) 2(1), 71–77
     
  18. Wagner T., Roth-Daniek A., Sell A., England J., Kern U. (2012)
    The capsaicin 8% patch for peripheral neuropathic pain: Review of treatment best practice from 'real world' clinical experience.
    Pain Manage 2012;2: 239-250
     
  19. Kern U., Nolte T. (2008)
    25 years of progress in pain therapy: the rocky road to recognition.
    MMW Fortschr Med 150, 115-117
     
  20. Kiefer T.-R., Kern U., Bredanger S. (2008)
    Chronische Knieschmerzen: ein außergewöhnlicher Fall.
    Angewandte Schmerztherapie 2, 45-48
     
  21. Kern U. (2006)
    Botulinumtoxin beim myofaszialen Schmerzsyndrom.
    Schmerztherapie Nr.1 18-19
     
  22. Kern U., in Fayyaz A., Jost W.-H. (ed.) (2003)
    BTX - A in the treatment of Phantom Pain.
    Wissenschaftsverlag Wellingsbüttel Hamburg
     
  23. Kern U., in Junker U., Nolte T. (ed.) (2005)
    Grundlagen der speziellen Schmerztherapie.
    Verlag Medizin & Wissen, München
     
  24. Kern U., in Ningel R., Funke W. (ed.) (1995)
    Soziale Netzwerke in der Praxis.
    Verlag für angewandte Psychologie, Göttingen
     
  25. Busch V., Magerl W., Kern U., Haas J., Hajak G., Eichhammer P. (2012)
    The effect of deep and slow breathing on pain perception, autonomic activity and mood processing.
    An experimental study
    Pain Med. 2012 Feb;13(2):215-28
     
  26. Kern U., England J., Roth-Daniek A., Wagner T.
    Is physician supervision of the capsaicin 8% patch administration procedure really necessary?
    An opinion from health care professionals
    J Pain Res. 2013 Jul 19;6:571-5
     
  27. Kern U., Nalamachu S., Brasseur L., Zakrzewska J.-M.
    Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?
    J Pain Res. 2013 Apr 5;6:261-80
     
  28. Kern U., Bialas P., Fangmann D.
    Prolonged-release tapentadol for phantom pain.
    A case series
    Schmerz. 2013 Apr 27;(2):174-81
     
  29. Treede R.-D., Wagner T., Kern U., Husstedt I.-W., Arendt G., Birklein F., Cegla T., Freynhagen R., Gockel H.-H., Heskamp M.-L., Jager H., Joppich R., Maier C., Leffler A., Nagelein H.-H., Rolke R., Seddigh S., Sommer C., Stander S., Wasner G., Baron R.
    Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
    Curr Med Res Opin. 2013 May 29&;(5):527-38
     
  30. Baron R., Kern U., Müller M., Dubois C., Falke D., Steigerwald I.
    Effectiveness and olerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
    Pain Pract. 2014 Apr 18
     
  31. Kern U., Nowack W., Poole C.
    Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
    Pain Pract. 2014 Feb 14;(2):E42-50
     
  32. Baron R, Kern U, Muller M et al. (2015)
    Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
    Pain practice : the official journal of World Institute of Pain 15:471-486
     
  33. Kern KU, Baust H, Hofmann W et al. (2014)
    Capsaicin 8 % cutaneous patches for phantom limb pain. Results from everyday practice (non-interventional study).
    Schmerz 28:374-383
     
  34. Kern KU, Bialas P, Fangmann D (2013)
    Prolonged-release tapentadol for phantom pain. A case series.
    Schmerz 27:174-181
     
  35. Kern KU, England J, Roth-Daniek A et al. (2013)
    Is physician supervision of the capsaicin 8% patch administration procedure really necessary? An opinion from health care professionals.
    Journal of pain research 6:571-575
     
  36. Kern KU, Krings D, Waldmann-Rex S (2014)
    Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone.
    MMW Fortschritte der Medizin 156 Suppl 2:54-63
     
  37. Kern KU, Nalamachu S, Brasseur L et al. (2013)
    Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?
    Journal of pain research 6:261-280
     
  38. Kern KU, Nowack W, Poole C (2014)
    Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
    Pain practice : the official journal of World Institute of Pain 14:E42-50
     
  39. Sanchez Del Aguila MJ, Schenk M, Kern KU et al. (2015)
    Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Clinical therapeutics 37:94-113
     
  40. Schlereth T, Heiland A, Breimhorst M et al. (2015)
    Association between pain, central sensitization and anxiety in postherpetic neuralgia.
    European journal of pain 19:193-201
     
  41. Treede RD, Wagner T, Kern KU et al. (2013)
    Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
    Current medical research and opinion 29:527-538
     
  42. Kern KU, Weiser T. (Dec. 2015)
    Topical ambroxol for the treatment of neuropathic pain : A first clinical observation.
    German version
    Schmerz, 29(6):632-40
    doi:10.1007/s00482-015-0065-6 (online verfügbar)
     
  43. Kern KU, Weiser T. (dec. 2015)
    Topical ambroxol for the treatment of neuropathic pain : An initial clinical observation.
    English version
    Schmerz, 29(Suppl 3):89-96
    (online verfügbar)

  44. Kern U (2013)
    Komponenten der Analgesie durch Akupunktur spezifiziert (Kommentar).
    JC Schmerzmed 2:213
     
  45. Kern U (2014)
    Die Faktoren für chronische Schmerzen nach Brustkrebs-OP (Kommentar).
    JC Schmerzmed 3:76-76
     
  46. Kern U (2015)
    Medikamentöse Kombinationstherapie bei Polyneuropathie (Kommentar).
    JC Schmerzmed 4:157-157
     
  47. Kern U (2015)
    Schmerzlinderung durch Berührung: Mechanismen genauer entschlüsselt (Kommentar).
    JC Schmerzmed 3:83
     
  48. Kern U (2016)
    Pharmakotherapie neuropathischer Schmerzen; Topische Therapien ergänzen bewährte systemische Konzepte.
    Deutsche Apothekerzeitung 156:46-52
     
  49. Kern U (2016)
    Neuraltherapeutische Injektionstechniken bei Rückenschmerz (Kommentar).
    JC Schmerzmed 5:129-129
     
  50. Baron R, Eberhart L, Kern KU et al. (2016)
    Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Pain practice : the official journal of World Institute of Pain
     
  51. Kern U (2016)
    Lokaltherapie mit Lidocain u. therapeutische Lokalanästhesie (Kap. 5); Lokaltherapie mit speziellen Substanzen (Kap. 7).
    In: Moderne Praxis der analgetischen Lokaltherapie, UNI-MED Science, 1. Aufl. (Editor C. Maihöfner)
     
  52. Lintzeris N, Bhaskar A, Kraus M et al. (2017)
    Consensus and controversies between pain and addiction experts on the prevention, diagnosis and management of opioid analgesic dependence.
    JAMA submitted
     
  53. Kern KU, Schwickert-Nieswandt M, Maihöfner C, Gaul C (2019)
    Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia - A New Option?
    Initial Clinical Case Observations. Headache. 2019 Mar;59(3):418-429
     
  54. Maihöfner C, Schneider S, Bialas P, Gockel H, Beer KG, Bartels M, Kern KU (2018)
    Successful treatment of complex regional pain syndrome with topical ambroxol: a case series.
    Pain Manag. 2018 Nov 1;8(6):427-436
     
  55. Poehlke T, Gralow I, Kern U et al. (2017)
    Empfehlungen zur Substitutionstherapie mit Buprenorphin/Naloxon bei behandlungsbedürftiger Medikamentenabhängigkeit von Opioiden.
    Sonderveröffentlichung
     
  56. Baron R, Treede RD, Birklein F et al. (2017)
    Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.
    Current medical research and opinion:1-25
     
  57. Kern U, Krings D, Waldmann-Rex S (2017)
    Tapentadol Prolonged Release Improves Analgesia, Functional Impairment and Quality of Life in Patients with Chronic Pain who have Previously Received Oxycodone/Naloxone.
    J Pain Relief 6:281.
    doi 10.4172/2167-0846.1000281
     
  58. Kern KU, Schwickert M (2017)
    Ambroxol for the treatment of fibromyalgia: science or fiction?
    Journal of pain research 10:1905-1929
     
  59. Kern KU, Schwickert-Nieswandt M (2019)
    Postherpetic neuralgia of the left trigeminus nerve V1: Successful therapy with capsaicin 8% patch.
    Schmerz 2018 Dec;32(6):464-467
     
  60. Kern KU (2019)
    Update Orthopädie
    Hot Topic: Schmerz. Orthopade 2019 Apr;48(4):348-349
     
  61. Kern KU, Sohns M, Heckes B, Elling C. (2020)
    Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life.
    Pain Manag. 2020 Mar;10(2):85-95
     
  62. Kraus M, Lintzeris N, Bhaskar A, Alho H, Alon E, Bouhassira D, Haro G, D'Agnone O, Dematteis M, Kern KU, Maremmani I, Perrot S, Sittl R, Pellicano K. (2020)
    Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder.
    J Addict Med. 2020 Jan/Feb;14(1):1-11
     
  63. Sachbuch (ab Herbst 2020):
    Mit einem Bein bereits im Himmel
    Phantomwahrnehmungen - auf den Spuren eines rätselhaften Phänomens

    Kai-Uwe Kern
    ISBN 978-3-456-86013-8
     
  64. Huygen F, Kern KU, Pérez C.
    Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain.
    J Pain Res. 2020 Oct 14;13:2585-2597

  65. Schubert T., Kern K.-U., Schneider S., Baron R.
    Oral or Topical Pain Therapy - How Would Patients Decide? A Discrete Choice Experiment in Patients with Peripheral Neuropathic Pain.
    Pain Pract. 2021 Jun;21(5):536-546
     
  66. Swidan S (Herausgeber), Bennett M (Herausgeber), Kern KU (Chapter author 'Fibromyalgia')
    Advanced Therapeutics in Pain Medicine
    Taschenbuch - CRC Press; 1. Edition (2020 Dec 20)
     
  67. Kern U.
    Hochdosiertes Capsaicin-Pflaster in der Behandlung peripherer neuropathischer Schmerzen. Ein Erfahrungsbericht mit 58 Patienten.
    Psychopharmakotherapie, 2012. 19: p. 72-5
     
  68. Kern K.-U., Vogelmann T., Tölle T. R.
    Tapentadol versus klassische WHO-III-Opioide bei chronischen Rückenschmerzen
    Versorgungsforschungsstudie auf Basis repräsentativer Krankenkassendaten
    MMW-Fortschritte der Medizin 2022; 164 (S6): 19–27